What is Gilead Sciences's SG&A?

Gilead Sciences (GILD) reported SG&A of $1.45B in Q1 2026.

How has Gilead Sciences's SG&A changed year-over-year?

Gilead Sciences's SG&A increased by 15.3% year-over-year, from $1.26B to $1.45B.

What is the long-term trend for Gilead Sciences's SG&A?

Over 4 years (2021 to 2025), Gilead Sciences's SG&A has grown at a 2.4% compound annual growth rate (CAGR), from $5.25B to $5.77B.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Gilead Sciences GILD SG&A

SG&A at other companies

Bristol-Myers SquibbBMY

$1.62B+2.1%

IncyteINCY

$328.09M+0.7%

PrecigenPGEN

$21.05M+70.3%

CelcuityCELC

$17.44M+174%

Vir Biotechnology, Inc.VIR

$23.34M-2.5%

ImmunityBio, Inc.IBRX

——

Segments

By segment

See full

Reportable Segment$1.45B+15.3%

Other financials

Income statement

See full

Revenue$7.0B+4.4%

Gross profit$5.5B+7.6%

Operating income$2.6B+15.6%

Net income$2.0B+53.7%

EPS (diluted)$1.61+54.8%

Balance sheet

See full

Cash & equivalents$7.6B-3.8%

Total debt$22.2B-11.1%

Total equity$23.5B+22.7%

Total assets$56.3B-0.3%

Cash flow

See full

Operating cash flow$2.5B+44.8%

CapEx$117.0M+12.5%

Free cash flow$2.4B+46.8%

Valuation

See full

Market cap$153.76B+13.9%

Enterprise value$168.3B+10.7%

P/E16.7×-5.9×

P/S5.2×+0.5×

Profitability

See full

Gross margin79.4%+1.1pp

Operating margin34.9%+6.3pp

Net margin31%+10.2pp

FCF margin34.4%+0.1pp

Returns & leverage

See full

Return on equity43.2%+10.7pp

Debt / equity0.9×-0.4×

Current ratio2×+0.6×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gilead Sciences's SG&A?: Gilead Sciences (GILD) reported SG&A of $1.45B in Q1 2026.
How has Gilead Sciences's SG&A changed year-over-year?: Gilead Sciences's SG&A increased by 15.3% year-over-year, from $1.26B to $1.45B.
What is the long-term trend for Gilead Sciences's SG&A?: Over 4 years (2021 to 2025), Gilead Sciences's SG&A has grown at a 2.4% compound annual growth rate (CAGR), from $5.25B to $5.77B.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.